Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

447 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment.
Ranganath LR, Milan AM, Hughes AT, Dutton JJ, Fitzgerald R, Briggs MC, Bygott H, Psarelli EE, Cox TF, Gallagher JA, Jarvis JC, van Kan C, Hall AK, Laan D, Olsson B, Szamosi J, Rudebeck M, Kullenberg T, Cronlund A, Svensson L, Junestrand C, Ayoob H, Timmis OG, Sireau N, Le Quan Sang KH, Genovese F, Braconi D, Santucci A, Nemethova M, Zatkova A, McCaffrey J, Christensen P, Ross G, Imrich R, Rovensky J. Ranganath LR, et al. Among authors: olsson b. Ann Rheum Dis. 2016 Feb;75(2):362-7. doi: 10.1136/annrheumdis-2014-206033. Epub 2014 Dec 4. Ann Rheum Dis. 2016. PMID: 25475116 Clinical Trial.
Interference of hydroxyphenylpyruvic acid, hydroxyphenyllactic acid and tyrosine on routine serum and urine clinical chemistry assays; implications for biochemical monitoring of patients with alkaptonuria treated with nitisinone.
Curtis SL, Norman BP, Milan AM, Gallagher JA, Olsson B, Ranganath LR, Roberts NB. Curtis SL, et al. Among authors: olsson b. Clin Biochem. 2019 Sep;71:24-30. doi: 10.1016/j.clinbiochem.2019.06.010. Epub 2019 Jun 20. Clin Biochem. 2019. PMID: 31228435
Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial.
Ranganath LR, Psarelli EE, Arnoux JB, Braconi D, Briggs M, Bröijersén A, Loftus N, Bygott H, Cox TF, Davison AS, Dillon JP, Fisher M, FitzGerald R, Genovese F, Glasova H, Hall AK, Hughes AT, Hughes JH, Imrich R, Jarvis JC, Khedr M, Laan D, Le Quan Sang KH, Luangrath E, Lukáčová O, Milan AM, Mistry A, Mlynáriková V, Norman BP, Olsson B, Rhodes NP, Rovenský J, Rudebeck M, Santucci A, Shweihdi E, Scott C, Sedláková J, Sireau N, Stančík R, Szamosi J, Taylor S, van Kan C, Vinjamuri S, Vrtíková E, Webb C, West E, Záňová E, Zatkova A, Gallagher JA. Ranganath LR, et al. Among authors: olsson b. Lancet Diabetes Endocrinol. 2020 Sep;8(9):762-772. doi: 10.1016/S2213-8587(20)30228-X. Epub 2020 Aug 18. Lancet Diabetes Endocrinol. 2020. PMID: 32822600 Clinical Trial.
Characterization of changes in the tyrosine pathway by 24-h profiling during nitisinone treatment in alkaptonuria.
Ranganath LR, Milan AM, Hughes AT, Davison AS, Khedr M, Norman BP, Bou-Gharios G, Gallagher JA, Gornall M, Jackson R, Imrich R, Rovensky J, Rudebeck M, Olsson B. Ranganath LR, et al. Among authors: olsson b. Mol Genet Metab Rep. 2022 Feb 1;30:100846. doi: 10.1016/j.ymgmr.2022.100846. eCollection 2022 Mar. Mol Genet Metab Rep. 2022. PMID: 35242577 Free PMC article.
Comparing the Phenylalanine/Tyrosine Pathway and Related Factors between Keratopathy and No-Keratopathy Groups as Well as between Genders in Alkaptonuria during Nitisinone Treatment.
Ranganath LR, Milan AM, Hughes AT, Davison AS, Khedr M, Imrich R, Rudebeck M, Olsson B, Norman BP, Bou-Gharios G, Gallagher JA. Ranganath LR, et al. Among authors: olsson b. Metabolites. 2022 Aug 22;12(8):772. doi: 10.3390/metabo12080772. Metabolites. 2022. PMID: 36005644 Free PMC article.
Determinants of tyrosinaemia during nitisinone therapy in alkaptonuria.
Ranganath LR, Milan AM, Hughes AT, Davison AS, M K, Norman BP, Bou-Gharios G, Gallagher JA, Imrich R, Arnoux JB, Rudebeck M, Olsson B. Ranganath LR, et al. Among authors: olsson b. Sci Rep. 2022 Sep 27;12(1):16083. doi: 10.1038/s41598-022-20424-z. Sci Rep. 2022. PMID: 36167967 Free PMC article.
Radiological evolution of spinal disease in alkaptonuria and the effect of nitisinone.
Imrich R, Sedláková J, Úlehlová M, Gornall M, Jackson R, Olsson B, Rudebeck M, Gallagher J, Lukáčová O, Mlynáriková V, Stančík R, Vrtíková E, Záňová E, Zaťková A, Arnoux JB, Rovenský J, Luangrath E, Bygott H, Khedr M, Ranganath LR. Imrich R, et al. Among authors: olsson b. RMD Open. 2022 Oct;8(2):e002422. doi: 10.1136/rmdopen-2022-002422. RMD Open. 2022. PMID: 36270742 Free PMC article. Clinical Trial.
447 results